Roivant Sciences Q2 2026 Earnings Preview

* Roivant Sciences (ROIV [https://seekingalpha.com/symbol/ROIV]) is scheduled to announce Q2 earnings results on Monday, November 10th, before market open.
* The consensus EPS Estimate is -$0.30 [https://seekingalpha.com/symbol/ROIV/earnings/estimates] and the consensus Revenue Estimate is $6.92M (+54.5% Y/Y).
* Over the last 3 months, EPS estimates have seen 0 upward revisions [https://seekingalpha.com/symbol/ROIV/earnings/revisions] and 2 downward. Revenue estimates have seen 1 upward revision and 0 downward.

MORE ON ROIVANT SCIENCES

* Roivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript [https://seekingalpha.com/article/4825714-roivant-sciences-ltd-roiv-presents-at-bernstein-2nd-annual-global-healthcare-conference]
* Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 Transcript [https://seekingalpha.com/article/4825683-roivant-sciences-ltd-roiv-presents-at-bank-of-america-global-healthcare-conference-2025]
* Roivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call Transcript [https://seekingalpha.com/article/4712808-roivant-sciences-ltd-roiv-q1-2024-earnings-call-transcript]
* Baron Health Care Fund buys ABBV, UNH, ROIV; exits WAT and COO [https://seekingalpha.com/news/4509225-baron-health-care-fund-buys-abbv-unh-roiv-exits-wat-and-coo]
* Roivant and Pfizer-backed Priovant post late-stage trial win for dermatomyositis therapy [https://seekingalpha.com/news/4495623-roivant-pfizer-backed-priovant-post-late-stage-trial-win]